Alkem launches Favipiravir under the brand name Alfluenza in India for management of mild to moderate cases of COVID-19

The cases of COVID-19 is increasing significantly globally and India too is affected with around 50,000 new cases being added on a daily basis. In this backdrop, Alkem Laboratories Ltd. (Alkem) has launched Favipiravir under the brand name "Alfluenza" in India for the management of mild to moderate cases of COVID-19. Favipiravir is approved by DCGI (Drug Controller General of India) for restricted emergency use in India. Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.

Shares of Alkem Laboratories Ltd was last trading in BSE at Rs.2842 as compared to the previous close of Rs. 2927.2. The total number of shares traded during the day was 9829 in over 1564 trades.

The stock hit an intraday high of Rs. 2949 and intraday low of 2825. The net turnover during the day was Rs. 28303800.

Source : Equity Bulls

Keywords